Doctor smiling
Doctors analyzing x-Ray

Focused on Addressing Critical

Unmet Needs

Diakonos Oncology, a clinical-stage biotechnology entity, was founded to address the critical and unmet medical need of late-stage and aggressive cancers . With a FDA Fast Track designation and unprecedented results in cancers such as Glioblastoma Multiforme (GBM), Diakonos moves closer each day to changing patient outcomes for these difficult indications.

Based on research conducted at Baylor College of Medicine, Diakonos has been privileged to work with other leading cancer institutions such as MD Anderson and UTHealth Houston.

Diakonos Oncology

Team

Mike Wicks, MS

Mike Wicks, MS

CEO and Board Member

Dan Faust

Dan Faust

Chairman

Paul Lammers, MD

Paul Lammers, MD

Board Member

Jay Hartenbach

Jay Hartenbach

President, COO

Laura Aguilar, MD PhD

Laura Aguilar, MD PhD

CMO

Donna Rill

Donna Rill

CTO

Will Decker, PhD

Will Decker, PhD

CSO

Ian Bellayr, PhD

Ian Bellayr, PhD

Chief Regulatory Officer

Deancy Okoebor

Deancy Okoebor

VP of Clinical Operations

Traci Fontenot

Traci Fontenot

VP, Quality

Vanaja Konduri, PhD

Vanaja Konduri, PhD

VP of R&D

Marcus Gohlke, CPA

Marcus Gohlke, CPA

Finance Director

Eva Schumann

Eva Schumann

Project Coordinator

Kam Spoto

Kam Spoto

Clinical Trial Manager

Nicole Stark

Nicole Stark

Data Quality Analyst

Olivia Okeobor

Olivia Okeobor

Clinical Research Assistant

Diakonos Oncology

Consultants

Elizabeth Duus

Elizabeth Duus

Clinical

Miya Parker

Miya Parker

Clinical

Sonja Nelson

Sonja Nelson

Finance

Chris Ayers

Chris Ayers

CMC

Uday Bandaru

Uday Bandaru

Quality

Lorraine Hicks

Lorraine Hicks

Logistics